About this Research Topic
Growth hormone deficiency (GHD) is a rare cause of short stature in children and adolescents, with a wide range of prevalence across different populations. While discussions continue over the use of growth hormone stimulation tests and the interpretation of their results, great advances have been made with the help of neuroimaging and genetics.
Recombinant human growth hormone (rhGH) is used to treat GHD. While daily injections are the current standard of care, adherence to this regimen can be challenging, often leading to reduced treatment efficacy. Long-acting growth hormone (LAGH) formulations offer an alternative that may improve adherence, simplify treatment, and potentially enhance patient outcomes.
This Research Topic aims to evaluate the efficacy, safety, and adherence to long-acting growth hormone therapy compared to daily GH injections in pediatric patients with GHD. We also seek research on diagnostic and treatment challenges in GHD, including socioeconomic barriers to access, and studies that explore potential biomarkers for short stature, including GHD. Additionally, this collection will examine the clinical, auxological, MRI characteristics and genetics of pediatric GHD patients to provide a comprehensive view of this condition and its treatment options.
We welcome articles addressing, but not limited to, the following themes:
• The efficacy, safety, and adherence of once-weekly subcutaneous growth hormone compared to daily growth hormone injections in children with GHD.
• Identification of potential biomarkers of short stature and GHD through metabolomic analysis.
• Auxological, clinical, MRI features and genetics of pediatric patients with isolated GHD.
• Epidemiological studies on the prevalence and characteristics of pediatric GHD across diverse populations.
• Access and socioeconomic barriers to diagnostic tests and treatment options for children with GHD.
By bringing together studies on long-acting growth hormone therapy and its impact on adherence, as well as on the diagnostic and treatment landscape of GHD, this Research Topic aims to support the development of more effective, patient-centered approaches to managing pediatric GHD.
Recombinant human growth hormone (rhGH) is used to treat GHD. While daily injections are the current standard of care, adherence to this regimen can be challenging, often leading to reduced treatment efficacy. Long-acting growth hormone (LAGH) formulations offer an alternative that may improve adherence, simplify treatment, and potentially enhance patient outcomes.
This Research Topic aims to evaluate the efficacy, safety, and adherence to long-acting growth hormone therapy compared to daily GH injections in pediatric patients with GHD. We also seek research on diagnostic and treatment challenges in GHD, including socioeconomic barriers to access, and studies that explore potential biomarkers for short stature, including GHD. Additionally, this collection will examine the clinical, auxological, MRI characteristics and genetics of pediatric GHD patients to provide a comprehensive view of this condition and its treatment options.
We welcome articles addressing, but not limited to, the following themes:
• The efficacy, safety, and adherence of once-weekly subcutaneous growth hormone compared to daily growth hormone injections in children with GHD.
• Identification of potential biomarkers of short stature and GHD through metabolomic analysis.
• Auxological, clinical, MRI features and genetics of pediatric patients with isolated GHD.
• Epidemiological studies on the prevalence and characteristics of pediatric GHD across diverse populations.
• Access and socioeconomic barriers to diagnostic tests and treatment options for children with GHD.
By bringing together studies on long-acting growth hormone therapy and its impact on adherence, as well as on the diagnostic and treatment landscape of GHD, this Research Topic aims to support the development of more effective, patient-centered approaches to managing pediatric GHD.
Keywords: Growth Hormone Deficiency (GHD), Long-acting Growth Hormone Therapy (LAGH), Pediatric Endocrinology, Short Stature, Biomarkers
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
